877 The effects of medroxyprogesterone acetate (MPA) on appetite (AP), weight (WT) and quality of life (QL) in advanced stage cancer

Autor: J.F. Vansleenkiste, G.P.M. ten Velde, G. H. Blijham, Neil K. Aaronson, Jean Simons, H. F. P. Hillen, E. F. M. Wouters
Rok vydání: 1995
Předmět:
Zdroj: European Journal of Cancer. 31:S183
ISSN: 0959-8049
Popis: Anorexia and cachexia are well known sequelae of advanced cancer, having a negative influence on quality of life and survival. In the present randomized double-blind placebo (PLA) controlled multicenter study in 206 incurable advanced stage non-hormone-sensitive cancer patients with a weight loss of 8.6 ± 7.9% of pre-illness weight, we studied the effects of the synthetic progestagen MPA (Farlutal® 500 mg b.i. d. for 12 weeks) on AP (0–10 pt numerical rating scale), WT and QL (EORTC QLQ-C30 questionnaire). An efficacy evaluable analysis (repeated measures ANOVA, two-sided) after 12 weeks of treatment could be performed in 99 patients (53 MPA, 46 PLA). Compared with the PLA group, a significant beneficial effect of MPA on AP and WT was found: mean difference in AP and WT change respectively 1.4 (P = 0.010) and 2.0 kg (P = 0.040). QL assessment revealed a significant worsening of physical-, role- and cognitive functioning, dyspnea and constipation in the total group of patients. There were, however, no significant differences in changes of QL between the MPA and PLA treated patients. No significant side effects of MPA were observed. We conclude that in weight-losing cancer patients MPA induces a significant improvement of AP and WT We did not find a measurable effect on general QL.
Databáze: OpenAIRE